Condition: Macrosomia, Fetal · Gestational Diabetes Mellitus in Pregnancy · Sponsor: University Hospital, Bordeaux
Gestational diabetes mellitus (GDM) increases the risk of macrosomia and other adverse pregnancy outcomes. Screening strategies are debated: universal vs. selective, and macrosomia may begin before the time of screening, suggesting that glycation markers may have an interest. The objective of this trail is to compare novel markers: skin autofluorescence and glycated albumin, to HbA1c (reference) as predictors of GDM, macrosomia and other adverse outcomes, in pregnant women.
This description comes directly from the study's public registry record.
FOUSSARD NINON, Dr · 5.57.65.60.78 · ninon.foussard@u-bordeaux.fr
RIGALLEAU VINCENT, Pr · 5.57.65.60.78 · vincent.rigalleau@chu-bordeaux.fr
Always discuss trial participation with your own doctor first.
| Hopital Pellegrin | Bordeaux, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06048510